Gilead Sciences, Inc [GILD] stock is trading at $93.40, up 0.90%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GILD shares have gain 1.47% over the last week, with a monthly amount glided 4.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on November 15, 2024, and set its price target to $110. On November 14, 2024, Citigroup initiated with a Buy rating and assigned a price target of $125 on the stock. Maxim Group downgraded its rating to a Hold. Leerink Partners upgraded its rating to a Outperform and raised its price target to $96 on October 21, 2024. Bernstein started tracking with a Outperform rating for this stock on October 17, 2024, and assigned it a price target of $105. In a note dated October 07, 2024, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $78 to $100.
Gilead Sciences, Inc [GILD] stock has fluctuated between $62.07 and $98.90 over the past year. Currently, Wall Street analysts expect the stock to reach $88.11 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $93.40 at the most recent close of the market. An investor can expect a potential drop of -5.66% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc [NASDAQ:GILD] reported sales of 28.27B for the trailing twelve months, which represents a growth of 7.05%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.3%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.01 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 92.29 points at the first support level, and at 91.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 94.02, and for the 2nd resistance point, it is at 94.63.
Ratios To Look Out For
For context, Gilead Sciences, Inc’s Current Ratio is 1.26. Also, the Quick Ratio is 1.10, while the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 4.18, the price to book ratio is 6.30 and price to earnings (TTM) ratio is 1052.99.
Transactions by insiders
Recent insider trading involved GILEAD SCIENCES, INC., 10% Owner, that happened on Dec 19 ’24 when 0.94 million shares were purchased. 10% Owner, GILEAD SCIENCES, INC. completed a deal on Dec 18 ’24 to buy 1.76 million shares. Meanwhile, Chief Financial Officer Dickinson Andrew D sold 8500.0 shares on Dec 16 ’24.
